Loading stock data…
FDMT
$9.09+0.22 (+2.48%)
Market ClosedLast close May 1
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
4D Molecular Therapeutics, Inc. in the Healthcare sector is trading at $9.09. The stock is currently 26% below its 52-week high of $12.34, remaining 5.1% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why FDMT maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.09
Potential Upside
5%
Whystock Fair Value$9.54
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$28.78+216.6%
Range$17.00 – $38.00
Fundamentals
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$490.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.80%
Volume
Today's trading volume
689,028
Recent News
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) provided updates on the company’s late-stage ophthalmology program, commercialization planning, cystic fibrosis development efforts, and cash runway during an appearance at the 2026 Leerink Partners Global Healthcare Conference in Miami. Phase
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and commercialization plans during a Barclays analyst discussion in Miami, highlighting its lead retinal program 4D-150 and an earlier-stage effort in cystic fibrosis. Company ov
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the top gene therapy stocks to buy according to hedge funds. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD), on February 9. 4FRONT-1 is a Phase 3 multicenter, […]